Company Overview

ExploraMed's primary mission is to significantly improve the quality of life for patients through fresh paradigms which create value for our customers and shareholders.

ExploraMed is a venture-backed medical technology incubation company dedicated to the identification, creation and development of new medical device solutions. ExploraMed creates new ideas which match certain key fundamental criteria and add captial, intellectual property, and expertise in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development. 

Partnered with New Enterprise Associates and several key business and clinical leaders from the medical technology industry, ExploraMed has the capability to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures and companies.  

ExploraMed I, founded in 1995, created two medical device companies, EndoMatrix Inc., and TransVascular Inc. EndoMatrix was created to develop a novel approach for tissue bulking in incontinence and GI Reflux, and was acquired by C.R. Bard Inc. in 1997. TransVascular, Inc. was created to develop several novel revascularization technologies including percutaneous coronary and peripheral bypass and cell injection technologies for cardiac regeneration, and was acquired by Medtronic Inc. in 2003. 

ExploraMed II, founded in 2004, produced two new businesses, Acclarent Inc. and NeoTract Inc.  Acclarent Inc., a company focused on developing several new technologies in the field of ENT, moved to its own facility in January 2005.  Acclarent, Inc. is currently commercializing its technology and has received over $103.5MM in venture funding from New Enterprise Associates, Versant Ventures, Delphi Ventures, Meritech Captial Partners, Johnson & Johnson Development Corporation. NeoTract Inc., left ExploraMed II in February 2006 and has raised $22MM in venture funding from New Enterprise Associates and others.  Neotract is in the clinical development phase and is pursuing a technology in the urology industry.

ExploraMed III, founded in 2006 has already produced Vibrynt, Inc., and Moximed Inc. Vibrynt, focused on the field of obesity, is currently in the clinical development phase, moved to its own facility in 2007 and has raised $46MM in venture funding to date from New Enterprise Associates, Delphi Ventures, and Texas Pacific Group (TPG) . Moximed, focused on the field of orthopedics, moved to its own facility in 2008 and has raised over $20MM in venture funding from New Enterprise Associates and Morgenthaler Ventures.